|Bid||51.25 x 100|
|Ask||56.61 x 600|
|Day's Range||56.36 - 57.78|
|52 Week Range||42.62 - 86.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jim Cramer sat down with Dexcom President and CEO Kevin Sayer, who said Abbott's glucose monitoring products have "nothing" on Dexcom's.
In fiscal 4Q17, Abbott Laboratories(ABT) invested ~6.9% of its total sales in R&D (research and development). In fiscal 2018, the company plans to invest ~7.5% of its total sales. Abbott Laboratories launched more than 20 new products in fiscal 2017. Abbott Laboratories now has an attractive product pipeline, boosted by the recent acquisitions—especially its acquisition of St. Jude Medical.
Johnson & Johnson (JNJ) released its 4Q17 and fiscal 2017 results on January 23, 2018. The company reported sales growth across its three business segments: Pharmaceuticals, Medical Devices, and Consumer Businesses. The company’s medical device business contributed ~35% to J&J’s total sales in fiscal 4Q17.
A recent report claims that the company has been working for months to develop a version of Fitbit for kids. Several unnamed sources spoke about the matter, but didn’t provide details on how the devices would differ from current ones. The idea of developing a version of Fitbit for kids makes sense.
Fitbit Inc (NASDAQ:FIT) confirmed that it has made its first investment in a startup, in an effort to beat Apple Inc.’s (NASDAQ:AAPL) Apple Watch. The Fitbit investment is in a company called Sano, which aims to develop a wearable, coin-sized blood sugar monitor for diabetics. FIT stock popped on the news on Friday morning, but is now down 2.5% shortly after the bell Monday morning.
Abbott's FreeStyle Libre continuous glucose monitor received Medicare reimbursement, the company said Thursday.
Abbott Laboratories said on Thursday its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States. The device, FreeStyle Libre Flash, was approved by the U.S. Food and Drug Administration in September. It allows diabetes patients to continuously track blood sugar levels without having to prick their fingers.
The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom
Standing at the threshold of 2018 it is imperative for the investors to find the means which can dilute the macroeconomic woes and help them gain more.
DexCom's (DXCM) collaborative agreements should bring in cash in the form of milestone payments and royalties, and help expand product portfolio.
Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for DexCom, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DexCom, Inc. Here are 5 ETFs with the largest exposure to DXCM-US. Comparing the performance and risk of DexCom, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)